BC 3448
Alternative Names: BC-3448Latest Information Update: 01 Dec 2023
At a glance
- Originator Biocity Biopharmaceutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA, China (Parenteral), prior to December 2023 (Biocity Biopharmaceutics pipeline, December 2023)
- 09 Sep 2023 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 24th World Conference on Lung Cancer (WCLC -2023)
- 07 Aug 2023 US FDA approves IND application for BC 3448 in Solid tumours